Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
MyelofibrosisEssential ThrombocythemiaMPN
Interventions
DRUG

Peptide-based vaccine

ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only). Mutant-CALR vaccine will administered every 2 weeks for the first 4 doses and then every 4 weeks for additional 6 doses. Maintenance Treatment The protocol allows for a continued administration of up to four (4) additional Mutant-CALR vaccine and four (4) Poly-ICLC administrations, 12 weeks apart.

DRUG

Poly ICLC

ten (10) doses of Poly-ICLC. Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31. each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination.

Trial Locations (1)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Marina Kremyanskaya

OTHER